Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Vor Biopharma Inc. (NYSE:VORGet Rating) have been assigned a consensus rating of “Buy” from the eight brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $24.47.

Several research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $26.00 target price on shares of Vor Biopharma in a report on Tuesday, March 15th. The Goldman Sachs Group assumed coverage on Vor Biopharma in a report on Wednesday, April 27th. They issued a “neutral” rating and a $6.00 target price on the stock. JMP Securities reduced their target price on Vor Biopharma from $30.00 to $15.00 in a report on Friday. Barclays reduced their target price on Vor Biopharma from $56.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, March 21st. Finally, B. Riley reduced their target price on Vor Biopharma from $60.00 to $46.00 in a report on Monday, January 24th.

VOR stock opened at $4.22 on Friday. Vor Biopharma has a 1-year low of $4.13 and a 1-year high of $23.96. The firm has a market cap of $158.29 million, a P/E ratio of -2.01 and a beta of -0.38. The business’s 50 day moving average is $6.33 and its 200-day moving average is $9.64.

Vor Biopharma (NYSE:VORGet Rating) last released its quarterly earnings data on Monday, March 14th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.06. On average, research analysts expect that Vor Biopharma will post -2.41 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of VOR. BlackRock Inc. lifted its stake in shares of Vor Biopharma by 24.2% in the 4th quarter. BlackRock Inc. now owns 1,403,327 shares of the company’s stock valued at $16,307,000 after purchasing an additional 273,289 shares during the period. Johnson & Johnson acquired a new position in shares of Vor Biopharma in the 3rd quarter valued at $16,851,000. Laurion Capital Management LP lifted its stake in shares of Vor Biopharma by 30.4% in the 4th quarter. Laurion Capital Management LP now owns 857,308 shares of the company’s stock valued at $9,962,000 after purchasing an additional 200,000 shares during the period. OUP Management Co. LLC acquired a new position in shares of Vor Biopharma in the 4th quarter valued at $4,354,000. Finally, Thrivent Financial for Lutherans lifted its stake in shares of Vor Biopharma by 0.8% in the 4th quarter. Thrivent Financial for Lutherans now owns 306,143 shares of the company’s stock valued at $3,558,000 after purchasing an additional 2,345 shares during the period. 83.11% of the stock is currently owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile (Get Rating)

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

See Also

Analyst Recommendations for Vor Biopharma (NYSE:VOR)

Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.